Trials / Completed
CompletedNCT04055883
Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD
A Multicenter, Double-blind, Placebo-controlled, Stratified-randomized, Parallel, Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-1229 in Patients With Calcific Aortic Valve Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 228 (actual)
- Sponsor
- Dong-A ST Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of DA-1229 in patients with calcific aortic valve disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DA-1229 | All participants are administered one tablet per day for 96 weeks |
Timeline
- Start date
- 2019-08-26
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
- First posted
- 2019-08-14
- Last updated
- 2023-03-03
Locations
10 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04055883. Inclusion in this directory is not an endorsement.